On July 6, 2023, the Board of Directors of Titan Pharmaceuticals, Inc. held a meeting at which it determined that a majority of the Board is comprised of independent directors in accordance with Nasdaq Listing Rule 5605(b)(1)(A). The Board also determined the composition of the Board committees for the upcoming year. The committees of the Board will be constituted as follows: Audit Committee: David Natan (Chair), Eric Greenberg, Matthew McMurdo, Compensation Committee: Matthew McMurdo (Chair), Peter Chasey, David Natan and Nominating and Governance Committee: Avraham Ben-Tzvi (Chair), Peter Chasey, Eric Greenberg.